is indicated for prophylactic use to reduce pre-operative
blood loss and the need for blood transfusion in patients
undergoing CardioPulmonary Bypass (CPB) in the course
of coronary artery bypass graft surgery.
The effects of Aprotinin use in CPB involve a reduction
in systemic inflammatory response, which translates
into a decreased need for allogeneic blood transfusions,
reduced bleeding and decreased mediastinal reexploration